Top

Published in:

01-01-2022 | Radiotherapy | Clinical study

Cabozantinib associated with excessive toxicity for salivary gland cancer in phase II trial

Published in: Reactions Weekly | Issue 1/2022

Excerpt

A phase II trial assessing the efficacy and safety of cabozantinib for patients with recurrent and/or metastatic salivary gland cancer (SGC) was halted early due to excessive toxicity, in particular due to severe wound complications in previously irradiated areas. …

van Boxtel W, et al. Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and/or metastatic salivary gland cancer. European Journal of Cancer : 14 Dec 2021. Available from: URL: http://doi.org/10.1016/j.ejca.2021.10.033

Title: Cabozantinib associated with excessive toxicity for salivary gland cancer in phase II trial
Publication date: 01-01-2022
Publisher: Springer International Publishing
Keywords: Radiotherapy
Diarrhea
Diarrhea
Cabozantinib
Salivary Gland Cancer
Salivary Gland Cancer
Published in: Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-07674-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cabozantinib associated with excessive toxicity for salivary gland cancer in phase II trial

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Bendamustine/rituximab

Baclofen

Tacrolimus

Methylprednisolone

Alteplase

Oxaliplatin